OCUGEN INC. - COMMON STOCK

0,7800

24-января-25 15:45:00

15 мин. задержка

Акции

9.9999999999989E-05

+0,01%

Сегодняшний диапазон

0,7701 - 0,8199

ISIN

N/A

Источник

NASDAQ

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 апр 2024 05:45:00 Источник Nasdaq GlobeNewswire
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 08:05:24 Источник Nasdaq GlobeNewswire
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 05:30:40 Источник Nasdaq GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 апр 2024 06:13:05 Источник Nasdaq GlobeNewswire
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 апр 2024 06:30:34 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 апр 2024 06:02:26 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 апр 2024 05:30:43 Источник Nasdaq GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 апр 2024 06:02:21 Источник Nasdaq GlobeNewswire
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 апр 2024 07:00:39 Источник Nasdaq GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 апр 2024 17:08:46 Источник Nasdaq GlobeNewswire
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 апр 2024 16:43:45 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 мар 2024 05:30:50 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 мар 2024 07:00:54 Источник Nasdaq GlobeNewswire
Ocugen to Present at Investing in Cures Summit

06 мар 2024 06:30:09 Источник Nasdaq GlobeNewswire
Ocugen Clinical Showcase Webcast Now Available

28 фев 2024 07:00:26 Источник Nasdaq GlobeNewswire
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26 фев 2024 07:30:13 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

22 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
Ocugen to Present at 2024 BIO CEO & Investor Conference

21 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

14 фев 2024 06:30:49 Источник Nasdaq GlobeNewswire
Ocugen to Present at Pharma Market Research Conference

31 янв 2024 07:00:12 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.